We are live on ! Find out more
SPRY icon

ARS Pharmaceuticals

4.76 USD
-0.30
5.93%
At close Updated Sep 11, 4:00 PM EDT
Pre-market
After hours
4.75
-0.01
0.21%
1 day
-5.93%
5 days
-15%
1 month
-20%
3 months
-50.36%
6 months
-43.2%
Year to date
-58.57%
1 year
-53.1%
5 years
-68.05%
10 years
-80.96%
 

About: ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.

Employees: 200

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 1.1%
Neutral 97.3%
Negative 1.6%
Neutral
GlobeNewsWire
1 day ago
ROSEN, LEADING INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPRY
NEW YORK, Sept. 12, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) between March 9, 2026 and June 24, 2026, inclusive (the “Class Period”), of the important October 5, 2026 lead plaintiff deadline.
ROSEN, LEADING INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPRY
Neutral
Newsfile Corp
1 day ago
SPRY UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ARS Pharmaceuticals To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in ARS Pharmaceuticals between March 9, 2026 and June 24, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - September 12, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against ARS Pharmaceuticals Inc. (""ARS Pharmaceuticals" or the "Company") (NASDAQ: SPRY) and reminds investors of the October 5, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
SPRY UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026
Neutral
GlobeNewsWire
2 days ago
Robbins LLP Reminds Investors of the Securities Fraud Class Action Lawsuit Against ARS Pharmaceuticals Inc. Following a More Than 23% Stock Drop on June 25, 2026
SAN DIEGO, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds shareholders that a securities class action has been filed on behalf of all investors who purchased or otherwise acquired ARS Pharmaceuticals Inc. (NASDAQ: SPRY) securities between March 9, 2026 and June 24, 2026 (the "Class Period").
Robbins LLP Reminds Investors of the Securities Fraud Class Action Lawsuit Against ARS Pharmaceuticals Inc. Following a More Than 23% Stock Drop on June 25, 2026
Neutral
PRNewsWire
2 days ago
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit
NEW YORK, Sept. 11, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) between March 9, 2026 and June 24, 2026, inclusive (the "Class Period"), of the important October 5, 2026 lead plaintiff deadline.
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit
Neutral
Newsfile Corp
2 days ago
Bronstein, Gewirtz & Grossman LLC Urges ARS Pharmaceuticals Inc. Investors to Act: Class Action Filed Alleging Investor Harm
New York, New York--(Newsfile Corp. - September 11, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against ARS Pharmaceuticals Inc. (NASDAQ: SPRY) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired ARS securities between March 9, 2026 and June 24, 2026, both dates inclusive (the "Class Period").
Bronstein, Gewirtz & Grossman LLC Urges ARS Pharmaceuticals Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Neutral
GlobeNewsWire
2 days ago
Bragar Eagel & Squire, P.C. Reminds ARS Pharmaceuticals Investors to Contact the Firm Before October 5th Seeking Lead Plaintiff Role
If you purchased or acquired ARS securities between March 9, 2026, and June 24, 2026 and would like to discuss your legal rights, contact Bragar Eagel & Squire partners Brandon Walker or Melissa Fortunato by email at [email protected] or by telephone at (212) 355-4648.
Bragar Eagel & Squire, P.C. Reminds ARS Pharmaceuticals Investors to Contact the Firm Before October 5th Seeking Lead Plaintiff Role
Neutral
GlobeNewsWire
2 days ago
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
LOS ANGELES, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ARS Pharmaceuticals, Inc. (“ARS” or “the Company”) (NASDAQ: SPRY) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
Neutral
Newsfile Corp
2 days ago
SPRY SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ARS Pharmaceuticals To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in ARS Pharmaceuticals between March 9, 2026 and June 24, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - September 11, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against ARS Pharmaceuticals Inc. (""ARS Pharmaceuticals" or the "Company") (NASDAQ: SPRY) and reminds investors of the October 5, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
SPRY SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026
Neutral
Newsfile Corp
3 days ago
Kaplan Fox Notifies Investors of ARS Pharmaceuticals Inc. (SPRY) of a Securities Fraud Class Action Deadline on October 5, 2026
New York, New York--(Newsfile Corp. - September 10, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against ARS Pharmaceuticals Inc. ("ARS" or the "Company") (NASDAQ: SPRY) on behalf of investors that purchased or otherwise acquired ARS securities between March 9, 2026 and June 24, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in ARS and have suffered losses, you may CLICK HERE to contact us.
Kaplan Fox Notifies Investors of ARS Pharmaceuticals Inc. (SPRY) of a Securities Fraud Class Action Deadline on October 5, 2026
Neutral
GlobeNewsWire
3 days ago
Bronstein, Gewirtz & Grossman LLC Urges ARS Pharmaceuticals Inc. Investors to Act: Class Action Filed Alleging Investor Harm
NEW YORK, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against ARS Pharmaceuticals Inc. (NASDAQ: SPRY) and certain of its officers.
Bronstein, Gewirtz & Grossman LLC Urges ARS Pharmaceuticals Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Price charts implemented using Lightweight Charts™